GlassScriptPhysician profile
Genna Siemons
NPI 1902210388
$4,097.33
in general payments reported to CMS, 2019-2025
45 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $266 · 2021: $886 · 2022: $654 · 2023: $793 · 2024: $497 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $585.07 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $414.04 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $277.48 | 2019-2025 | Otezla, Otezla, Repatha |
| Astellas Pharma US INC | $173.37 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $170.95 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $155.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.36 | 2019-2025 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $91.16 | 2023-2025 | |
| Biogen, INC. | $84.96 | 2021-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $79.85 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.25 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $70.90 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.14 | 2021-2024 | Xifaxan |
| Daiichi Sankyo INC. | $59.25 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genna Siemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.